From risk to fairness.
Kadcyla is a drug that extends the life of breast cancer patients by an average of 6 mo. It also happens to be incredibly expensive. The United Kingdom’s National Health Service sparked controversy when it refused to provide this drug to patients, citing its low cost effectiveness. Cases like this r...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
National Academy of Sciences
2016
|